Amgen's Repatha hits wall at SCOTUS but presses ahead—new price breaks included
Amgen has been trying since 2015 to protect its PCSK9 cholesterol drug Repatha by keeping Sanofi and Regeneron's rival Praluent off the market, even going as far as to ask the U.S. Supreme Court to review an ongoing patent fight.
But that attempt fell short this week as SCOTUS refused to hear the company's appeal of a 2017 court decision allowing Sanofi and Regeneron to continue selling its head-to-head rival.
Amgen isn't giving up the fight, though. The company is prepping for a new...